Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.
Investigators monitored fetal haemoglobin levels in 25 preterm neonates until 36 weeks of post‐menstrual age; patients received repeated red blood cell (RBC) units from allogeneic cord blood (cord‐RBCs) or from adult donors, depending on whether cord‐RBCs were available.
Teofili, L., Papacci, P., Orlando, N., Bianchi, M., Molisso, A., Purcaro, V., … Stefano, V. D. (n.d.). Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TrIP study. British Journal of Haematology, n/a(n/a). https://doi.org/10.1111/bjh.16851Cite